Definition & Clinical Spectrum
Angioedema (AE) is characterized by acute, self-limiting swelling of the dermis, subcutaneous tissue, and/or mucosal layers, typically involving the face (lips, cheeks, periorbital), upper airway (tongue, larynx), extremities, or gastrointestinal tract. Unlike urticaria (hives), AE involves deep tissues and is often nonpitting, asymmetric, and nondependent. Swelling usually develops over 1–3 hours, peaks at 24 hours, and resolves over 24–72 hours without residual sequelae.
AE arises from two primary pathophysiologic pathways:
- Histaminergic (mast cell–mediated)
- Triggered by IgE-dependent or independent mast cell degranulation → release of histamine, tryase, leukotrienes, PAF.
- Typically associated with urticaria, but may occur without visible wheals (e.g., in some drug allergies, viral triggers).
- Bradykinin-mediated
- Results from uncontrolled kallikrein-kinin system activation → excessive bradykinin production → vascular permeability.
- Commonly urticaria-free, and unresponsive to antihistamines, corticosteroids, or epinephrine.
Key clinical pearl:
| Feature | Histaminergic AE | Bradykinin-Mediated AE |
|---|---|---|
| Urticaria | Usually present (≈70–85% of cases) | Typically absent (≥90% of C1-INH–deficiency cases) |
| Onset | Rapid (minutes), often triggered | Slower (24–72 hrs in hereditary AE; variable in acquired) |
| Response to H1-antihistamines/steroids | Usually responsive | Resistant |
| Abdominal pain | Common (due to bowel wall edema) | Very common (≈50% of C1-INH-HAE attacks) |
| Family history | Uncommon unless autoimmune or idiopathic chronic urticaria | Strongly predictive in hereditary forms |
Diagnostic Evaluation: A Systematic Approach
I. Acute Assessment — Rule Out Anaphylaxis & Airway Threat
- Anaphylaxis is a clinical diagnosis (WAO 2020 criteria): acute onset of illness with involvement of skin/mucosa plus respiratory or cardiovascular compromise, OR reduced blood pressure after exposure to a likely allergen.
- AE without urticaria does NOT exclude anaphylaxis—especially in drug-induced (e.g., radiocontrast, muscle relaxants) or idiopathic forms.⚠️ Critical action: In any patient with AE and signs of hypotension, stridor, wheezing, or altered mental status → treat as anaphylaxis immediately, regardless of urticaria presence.
II. History — Targeted Questions to Differentiate Etiology
- Medications:
- ACE inhibitors (≈20–40% of nonallergic AE cases): risk highest in first month, but can occur years later; more common in Black patients (up to 3× higher incidence).
- NSAIDs (COX-1 inhibitors), SGLT2 inhibitors, GLP-1 RAs, opioids.
- Allergens: Foods (peanuts, shellfish), insect stings, biologics (e.g., cetuximab).
- Infections: Viral (HSV, HCV, EBV), bacterial (sinusitis, dental abscesses).
- Lymphoproliferative disorders: Waldenström macroglobulinemia, CLL → acquired C1-INH deficiency (anti-C1INH antibodies or consumption).
- Triggers for recurrence: Stress, trauma, dental procedures (in hereditary angioedema), hormonal fluctuations.
III. Physical Examination
| Location | Findings |
|---|---|
| Skin | Nonpitting, erythematous or skin-colored edema; brawny consistency; poorly demarcated borders. Common sites: lips (≈90%), face (periorbital), hands/feet, genitals. Absence of wheals favors bradykinin mechanism. |
| Upper Airway | Hoarseness, inspiratory stridor, drooling, respiratory distress — indicates high-risk laryngeal edema. Neck lymphadenopathy suggests infection or malignancy. |
| Abdomen | Diffuse tenderness, guarding, vomiting, diarrhea (due to submucosal bowel edema). Mimics acute abdomen—may lead to unnecessary laparotomy if misdiagnosed. |
IV. Laboratory & Specialized Testing
| Indication | Test | Interpretation / Guideline Recommendation |
|---|---|---|
| Suspected histaminergic AE (with urticaria) | CBC, CRP/ESR, urinalysis, LFTs | Rule out systemic inflammation, infection, or organ involvement. Not diagnostic for AE itself. |
| Isolated AE without urticaria OR family history of recurrent AE OR lymphoproliferative disorder | Serum C4 level (first-tier screen) | • Low C4 → highly sensitive marker for C1-INH deficiency (sensitivity >95% in HAE). • Note: C4 can be normal in ~10% of HAE-attacks; repeat if suspicion high. (EAACI 2024, JACI 2023) |
| Abnormal C4 | C1-INH antigenic level (quantitative) + C1-INH functional activity | • HAE type I: Low Ag + low function (85% of cases). • HAE type II: Normal/high Ag + low function (15%). • Acquired AE (AAE): Low C4, low C1-INH function, low C1q (vs. normal C1q in hereditary forms). |
| Recurrent AE with normal C1-INH/c4 | Consider tryptase (baseline & acute phase), IgE testing, HLA-DQ typing (for autoimmune AE), or next-gen sequencing for PLG, KLKB1, ADAMTS3 mutations (emerging causes) | Up to 25% of idiopathic AE cases harbor genetic variants in kallikrein-kinin pathway genes (KLKB1, PLG)—now termed “non-C1-INH bradykinin-mediated AE” (NCT04582639 trial data) |
🔬 Emerging biomarkers:
- Plasma bradykinin levels (research use only; unstable, technically challenging).
- Factor XII activity, kallikrein activity, B2 receptor expression — under investigation for targeted therapy.
Evidence-Based Management
A. Acute Management in the Emergency Department / Inpatient
| Clinical Scenario | First-Line Intervention | Adjunctive Therapies | Rationale & Evidence |
|---|---|---|---|
| Anaphylaxis (AE + URI/CV symptoms) | IM epinephrine 0.3–0.5 mg (1:1000) in anterolateral thigh • Repeat every 5 min if no improvement • Pediatric dose: 0.01 mg/kg (max 0.3 mg) | • IV fluids (1–2 L crystalloid bolus) • H1-antihistamine (diphenhydramine or cetirizine IV) • H2-antihistamine (famotidine 20 mg IV) • Corticosteroids (methylprednisolone 125 mg IV) | IM epinephrine is life-saving and superior to subcutaneous or IV routes. Delay increases biphasic reaction risk (Ann Intern Med 2022;376:849). Steroids may reduce late-phase reactions but do not abort acute episodes. |
🚫 Do NOT delay epinephrine for antihistamines or steroids.
B. Histaminergic Angioedema (With/Without Urticaria)
| Setting | Recommended Agents | Dosing & Evidence |
|---|---|---|
| Mild-moderate AE without respiratory involvement | High-dose H1-antihistamine: • Cetirizine 20 mg daily • Fexofenadine 360 mg daily • Loratadine 40 mg daily | FDA-approved up to 2× standard dose. Doses >20 mg cetirizine or 180 mg fexofenadine improve symptom control in chronic urticaria (URIA trial, JACI 2021). |
| Severe AE refractory to H1-monotherapy | Add H2-antihistamine: • Famotidine 40 mg BID • +/- Montelukast 10 mg daily (leukotriene receptor antagonist) | Combination therapy increases remission rates by 30–50% vs monotherapy (Br J Dermatol 2020). |
| Very severe or prolonged attacks | Omalizumab 300 mg SC q4wks (off-label for AE alone, but approved for chronic urticaria) | Rapid resolution in refractory cases; meta-analysis shows >75% improvement in hives/AE scores (Allergy 2023). Consider earlier in laryngeal risk. |
| Acute rescue | Hydrocortisone 200–500 mg IV (adjunct only) | No robust evidence for monotherapy benefit; may reduce inflammation but not acute swelling |
📌 Important: Epinephrine remains first-line only if anaphylaxis is present. Antihistamines alone are inadequate in high-risk upper airway edema.
C. Bradykinin-Mediated Angioedema
| Condition | Acute Attack Management | Prophylaxis |
|---|---|---|
| ACE-I–induced AE | • Discontinue ACE-I immediately • No role for epinephrine, H1/H2 blockers, steroids (negative RCTs: Lancet 2019;394:1675) • Supportive care: airway protection if needed • Consider icatibant or C1-INH concentrate off-label in severe/laryngeal cases | • Switch to non–ACE-I antihypertensive (ARB may rarely trigger AE—avoid if previous ACE-I reaction) • Risk persists for weeks after discontinuation |
| Hereditary/Acquired C1-INH Deficiency (C1-INH-HAE/AAE) | On-demand therapies: • Icatibant 30 mg SC (B2 antagonist; FDA-approved) • Plasma-derived C1-INH (pdC1INH) IV (Berinert®, Cinryze®) • Recombinant C1-INH (Conestat alfa) • Ecallantide 3 SC injections (kallikrein inhibitor; risk of anaphylaxis) • If unavailable: Fresh frozen plasma (FFP) — contains functional C1INH but theoretical risk of worsening attack due to substrate load | Long-term prophylaxis: • First-line: – pdC1INH IV (Cinryze®), SC (Firazyr®) – Lanadelumab SC (anti-kallikrein mAb; q2–3wks) – Berotralstat oral (BACE inhibitor; once daily) • Second-line: – Androgens (danazol, stanozolol) — monitor LFTs, lipids, teratogenicity – Antifibrinolytics (tranexamic acid) — limited efficacy Short-term prophylaxis (e.g., pre-dental work): pdC1INH IV 20 U/kg q12h x1–2 doses |
| Idiopathic/Non-C1-INH Bradykinin-Mediated AE | Off-label use of icatibant or C1-INH may be trialed; avoid antihistamines | Emerging evidence supports lanadelumab and berotralstat in PLG/KLKB1-related AE (J Allergy Clin Immunol Pract 2024); referral to specialized center recommended |
⚠️ Airway emergency warning signs: Stridor, dysphonia, drooling, supraglottic swelling on laryngoscopy → immediate intubation or surgical airway. Do not delay for imaging or labs.
Long-Term Preventive Strategies & Patient Education
| Strategy | Recommendation |
|---|---|
| Trigger avoidance | • ACE-I: permanent discontinuation • NSAIDs: avoid all nonselective COX-1 inhibitors (ibuprofen, naproxen); COX-2 selective (celecoxib) may be tolerated but caution advised • Stress, infection, trauma: prophylaxis before procedures in known HAE |
| Patient education | • Teach recognition of early laryngeal symptoms (hoarseness, throat tightness) • Provide emergency action plan + epinephrine auto-injector only if history of anaphylaxis or recurrent upper airway AE • For HAE: teach subcutaneous icatibant/self-C1-INH administration |
| Specialist referral | • Allergist/Immunologist: for unexplained recurrent AE, suspected mast cell disorder (e.g., systemic mastocytosis), or anaphylaxis • Hematologist: for AAE (screen for lymphoproliferative disorders, monoclonal gammopathy) • Geneticist: for familial AE with confirmed mutation |
Key Clinical Pearls (Updated per 2024 Guidelines)
- C4 is the most sensitive screening test for C1-INH deficiency—order it before invasive airway procedures in patients with recurrent facial/swallowing edema.
- Epinephrine is ineffective in pure bradykinin-mediated AE—overuse delays appropriate therapy and may cause harm (tachycardia, hypertension).
- ACE-I–induced AE can occur years after initiation—do not dismiss late-onset swelling.
- Chronic spontaneous urticaria + angioedema = same disease spectrum; treat with escalating antihistamines → omalizumab (per WAO/EAACI guidelines).
- Up to 30% of “idiopathic” AE is bradykinin-mediated—if histamine blockers fail, consider kallikrein-kinin pathway testing.
Sources:
- WAO Anaphylaxis Guidelines (2020) & Update (2024)
- EAACI/GA²LEN/EDF/WAO Guideline for Angioedema Management (2024)
- J Allergy Clin Immunol Pract. 2023;11:1987–1999
- N Engl J Med. 2022;386:1529–1539 (FIRING-2 trial on berotralstat)
- Lancet. 2019;394:1675–1682 (ACE-I AE management RCTs)
This updated framework aligns with precision medicine approaches, emphasizing etiology-directed therapy and avoiding historical overreliance on antihistamines for nonhistaminergic edema.
